CapForce (OPGN) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
19 Aug, 2026Executive summary
Transitioned from precision medicine to financial services and technology in 2024, focusing on listing sponsorship and consultancy for international companies.
Acquired Sun Investment Enterprises Limited (SIE) and its subsidiary iCapX in December 2025 to expand fintech and advisory capabilities.
Changed corporate name and ticker to CapForce Inc. (CFOR) in February 2026.
Financial highlights
Revenue for Q2 2026 was $50.0 million, up from $4.0 million in Q2 2025, driven by listing sponsorship services.
Net income for Q2 2026 was $42.5 million, compared to $3.5 million in Q2 2025.
Operating expenses rose to $5.7 million in Q2 2026 from $0.6 million in Q2 2025, mainly due to higher cost of services and G&A expenses.
Cash and cash equivalents were $0.1 million as of June 30, 2026.
Outlook and guidance
Plans to fund operations primarily through financing from AEI Capital until business is self-sustaining or investments are monetized.
$6.0 million of additional equity financing capacity remains available under the 2024 Securities Purchase Agreement.
Revenue is expected to remain transaction-driven and unpredictable in timing.
Latest events from CapForce
- Net loss increased to $0.7 million in Q1 2026, with no revenue and continued reliance on external financing.OPGN
Q1 2026 - 2025 revenue jumped to $30.2M, net income reached $23.6M, led by fintech and advisory growth.OPGN
Q4 2025 - All seven proposals, including director elections and a name change, were approved by majority vote.OPGN
AGM 2026 - Shareholders will vote on seven key proposals, including a new equity plan and company name change.OPGN
Proxy Filing - Shareholders will vote on key governance, compensation, and structural changes, including a name change.OPGN
Proxy Filing - Q2 2025 revenue reached $4.0M from listing sponsorship, with net income of $3.5M.OPGN
Q2 2025 - OpGen posted $8.9M Q3 net income, exited diagnostics, and secured $9M equity funding for fintech pivot.OPGN
Q4 2023 - OpGen's revenue collapsed and liquidity remains critical as it pursues a sale or strategic transaction.OPGN
Q2 2024 - Revenue plunged 82% as OpGen pivots to survival mode amid insolvencies and urgent funding needs.OPGN
Q1 2024